Kommentar zu „Rucaparib verlängert progressionsfreies Überleben bei metastasiertem Prostatakarzinom“

Dtsch Med Wochenschr 2023; 148(21): 1340-1341
DOI: 10.1055/a-2043-7616

Aktuell publiziert

Contributor(s):

Gunhild von Amsberg

Literatur
1 De Bono J. et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med 2020; 382: 2091-2102
2 Hussain M. et al. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer N Engl. J Med 2020; 383: 2345-2357
3 Bryce A. et al. Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy. Journal of Clinical Oncology 2023; 41 (Suppl. 06) 18-18